News|Articles|October 9, 2025
Streamline AAV-based Gene Therapies with High-Performing Off-the-Shelf Plasmids
Author(s)Catalent
Key Takeaways
Optimized plasmids are vital for viral vector production. Catalent’s off-the-shelf plasmids help AAV gene therapy developers enhance efficiency, reduce costs, and improve consistency across development and manufacturing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
2
Generative AI and Adaptive Trials Shape Future Biotech Development
3
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
4
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
5